All posts by: Michael Zand

About Michael Zand

Stem cell therapy for the heart: hype or hope? – The Business Times

Continue reading

2018-05-04 NEWS

The Business Times

Stem cell therapy for the heart: hype or hope?
The Business Times
STEM cell treatment continues to be bandied around as the “magic ” bullet for many health conditions. It is time to take stock of the state of technology concerning the use of stem cells in heart disease. The normal heart cell. The first thing we need
Fasting may boost stem cell regeneration: study – The HinduThe Hindu
Fasting boosts stem cells‘ regenerative capacityScienceBlog.com (blog)
Dr. Luga Podesta on stem cells in orthopedics, ‘a new frontier in medicine’Becker’s Orthopedic & Spine
The Tribune –Technology Networks –The Indian Express
all 34 news articles »
Continue reading

2018-05-04 NEWS

New Alzheimer’s and Parkinson’s Immunotherapy Data at AAN
Alzforum
For neurodegeneration researchers, highlights at the 2018 conference of the American Academy of Neurology, held April 21 to 27 in Los Angeles, California, were centiloid analysis of PET scans, the latest cognition update from people treated with the

Continue reading

2018-05-04 NEWS

New Alzheimer’s and Parkinson’s Immunotherapy Data at AAN
Alzforum
For neurodegeneration researchers, highlights at the 2018 conference of the American Academy of Neurology, held April 21 to 27 in Los Angeles, California, were centiloid analysis of PET scans, the latest cognition update from people treated with the

Continue reading

2018-05-04 NEWS

NJBIZ

Hackensack Meridian joins NJII’s gene therapy center
NJBIZ
Hackensack Meridian Health has become part the New Jersey Innovation Institute’s Cell and Gene Therapy Development Center. HMH will have access to NJII’s process development and clinical manufacturing capabilities, as well as the center’s training and

Continue reading

2018-05-04 NEWS

NJBIZ

Hackensack Meridian joins NJII’s gene therapy center
NJBIZ
Hackensack Meridian Health has become part the New Jersey Innovation Institute’s Cell and Gene Therapy Development Center. HMH will have access to NJII’s process development and clinical manufacturing capabilities, as well as the center’s training and